Video

Addressing Cancer Health Disparities

Disparities in cancer care are predominantly due to access issues, states Jeffery C. Ward, MD. Removing barriers to access, such as socioeconomic, language, and cultural barriers, will help to eliminate disparities.

An important component of addressing the high cost of care in the United States is focusing more on population health, says Michael Kolodziej, MD. It is important for individuals to be screened for cancer and to maintain a healthy lifestyle. Improving population health is the primary intent behind quality metrics, adds Kolodziej.

As the demand for oncologists increases, so does the need for payment reform, notes Ward. It is also essential to address the way care is delivered, states Kolodziej. Team-based care, such as within a patient-centered medical home, allows healthcare professionals to operate at the top of their licenses. Working as part of a team diffuses some of the individual responsibilities, adds Kolodziej, and enriches the career paths of its members.

Related Videos
Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia
In this episode of OncChats: A Close Look at Clinical Trials in Oncology and Beyond, Dr Carvajal discusses the progress made in cancer clinical trials, with nearly 20,000 trials worldwide and over 80 FDA-approved cancer drugs since 2015, while also noting the challenges posed by the increasing complexity of therapies and trial protocols.
Marcella Ali Kaddoura, MD
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.